Rosenblum MG - Search Results

1

Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.

Eton O, Rosenblum MG, Legha SS, Zhang W, Jo East M, Bedikian A, Papadopoulos N, Buzaid A, Benjamin RS. Eton O, et al. Among authors: rosenblum mg. Cancer. 2002 Jul 1;95(1):127-34. doi: 10.1002/cncr.10631. Cancer. 2002. PMID: 12115326 Free article. Clinical Trial.

2

Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.

Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj S. Murray JL, et al. Among authors: rosenblum mg. J Immunother Emphasis Tumor Immunol. 1996 May;19(3):206-17. doi: 10.1097/00002371-199605000-00005. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8811495 Clinical Trial.

3

Immunospecific saturable clearance mechanisms for indium-111-labeled anti-melanoma monoclonal antibody 96.5 in humans.

Murray JL, Lamki LM, Shanken LJ, Blake ME, Plager CE, Benjamin RS, Schweighardt S, Unger MW, Rosenblum MG. Murray JL, et al. Among authors: rosenblum mg. Cancer Res. 1988 Aug 1;48(15):4417-22. Cancer Res. 1988. PMID: 3390837

4

Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma.

Rosenblum MG, Murray JL, Haynie TP, Glenn HJ, Jahns MF, Benjamin RS, Frincke JM, Carlo DJ, Hersh EM. Rosenblum MG, et al. Cancer Res. 1985 May;45(5):2382-6. Cancer Res. 1985. PMID: 3986780

5

Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5.

Murray JL, Rosenblum MG, Sobol RE, Bartholomew RM, Plager CE, Haynie TP, Jahns MF, Glenn HJ, Lamki L, Benjamin RS, et al. Murray JL, et al. Among authors: rosenblum mg. Cancer Res. 1985 May;45(5):2376-81. Cancer Res. 1985. PMID: 3986779

6

Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.

Macey DJ, Grant EJ, Kasi L, Rosenblum MG, Zhang HZ, Katz RL, Rieger PT, LeBherz D, South M, Greiner JW, Schlom J, Podoloff DA, Murray JL. Macey DJ, et al. Among authors: rosenblum mg. Clin Cancer Res. 1997 Sep;3(9):1547-55. Clin Cancer Res. 1997. PMID: 9815842 Clinical Trial.

7

Penetration of methylglyoxal bis(guanylhydrazone) into intracerebral tumors in humans.

Rosenblum MG, Stewart DJ, Yap BS, Leavens M, Benjamin RS, Loo TL. Rosenblum MG, et al. Cancer Res. 1981 Feb;41(2):459-62. Cancer Res. 1981. PMID: 7448791

8

Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers.

LeMaistre CF, Craig FE, Meneghetti C, McMullin B, Parker K, Reuben J, Boldt DH, Rosenblum M, Woodworth T. LeMaistre CF, et al. Cancer Res. 1993 Sep 1;53(17):3930-4. Cancer Res. 1993. PMID: 8358720 Clinical Trial.

9

Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor.

Liu Y, Cheung LH, Marks JW, Rosenblum MG. Liu Y, et al. Among authors: rosenblum mg. Int J Cancer. 2004 Feb 10;108(4):549-57. doi: 10.1002/ijc.11524. Int J Cancer. 2004. PMID: 14696119

10

Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer.

Murray JL, Macey DJ, Kasi LP, Rieger P, Cunningham J, Bhadkamkar V, Zhang HZ, Schlom J, Rosenblum MG, Podoloff DA. Murray JL, et al. Among authors: rosenblum mg. Cancer. 1994 Feb 1;73(3 Suppl):1057-66. doi: 10.1002/1097-0142(19940201)73:3+<1057::aid-cncr2820731345>3.0.co;2-3. Cancer. 1994. PMID: 8306248 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

202 results

Search Page

Filters